深圳华大基因股份有限公司 关于持股 5%以上股东减持股份计划的预披露公告 持股 5%以上的股东深圳生华投资企业（有限合伙）保证向本公司提供的信息 内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 证券代码：300676 证券简称：华大基因 公告编号：2025-041 深圳华大基因股份有限公司（以下简称公司或上市公司）持股 5%以上股东深 圳生华投资企业（有限合伙）（以下简称生华投资）持有公司股份 34,470,455 股， 占公司总股本 418,317,075 股的 8.2403%。生华投资计划自本减持计划公告之日起 15 个交易日后的 3 个月内（2025 年 9 月 4 日—2025 年 12 月 3 日），通过集中竞 价、大宗交易方式减持公司股份不超过 6,274,756 股（即不超过公司总股本比例的 1.5000%）。 公司近日收到持股 5%以上的股东生华投资出具的《股份减持计划的告知函》， 现将有关情况公告如下： 一、股东的基本情况 （一） 股东名称 深圳生华投资企业（有限合伙） （二） 股东持股情况 | 深圳 ...

融券方面，当日融券卖出0.00万股，净买入0.05万股。 8月11日，沪深两融数据显示，华大基因获融资买入额0.39亿元，居两市第1197位，当日融资偿还额0.59 亿元，净卖出1994.48万元。 最近三个交易日，7日-11日，华大基因分别获融资买入0.93亿元、0.83亿元、0.39亿元。 ...

华大基因最新一期业绩显示，截至2025一季报，公司营业总收入6.72亿元、同比减少18.18%，归属净利 润5269.51万元，同比减少524.87%，扣非净利润6329.71万元，同比减少2879.13%，流动比率2.854、速 动比率2.617、资产负债率26.68%。 金融界消息 截至2025年8月11日收盘，华大基因（300676）报收于52.93元，上涨1.44%，换手率 1.75%，成交量7.28万手，成交金额3.85亿元。 资金流向方面，今日主力资金净流出1419.47万元，占比成交额3.69%。其中，超大单净流入774.32万 元、占成交额2.01%，大单净流出2193.79万元、占成交额5.7%，中单净流出流出2057.92万元、占成交 额5.35%，小单净流入3477.39万元、占成交额9.04%。 通过天眼查大数据分析，深圳华大基因股份有限公司共对外投资了71家企业，参与招投标项目42次，知 识产权方面有商标信息665条，专利信息375条，此外企业还拥有行政许可14个。 来源：金融界 天眼查商业履历信息显示，深圳华大基因股份有限公司，成立于2010年，位于深圳市，是一家以从事专 业技术服 ...

来源：金融界 主力资金净流出居前的分别为安杰思（1536.17万元）、科华生物（1457.06万元）、海利生物（1440.72 万元）、华大基因（1419.47万元）、福瑞股份（1329.15万元）。 序号代码名称最新价涨跌幅主力净流入主力净占比1300760迈瑞医疗230.5-0.098724.29万元 6.07%2300753爱朋医疗34.261.935531.45万元7.53%3300314戴维医疗15.2510.035504.85万元 11.77%4603658安图生物42.343.394457.47万元15.08%5688273麦澜德44.759.234025.59万元9.14%6002432 九安医疗40.121.192866.50万元6.27%7600587新华医疗18.144.432682.44万元3.88%8300453三鑫医疗 9.413.982472.80万元10.27%9688271联影医疗130.68-0.021943.47万元5.25%10603309维力医疗 14.92.831756.01万元10.29% 8月11日，医疗器械行业上涨1.65%，今日主力资金流出4.97亿元，成分 ...

Core Viewpoint - A case in the A-share market highlights the integration of health benefits into shareholder rewards, showcasing the effectiveness of the company's technology in a real-life scenario [1] Group 1: Company Initiatives - BGI Genomics (华大基因) launched a shareholder reward program in February 2025, allowing shareholders who have held shares for over a year to receive a free health screening kit [1] - The company emphasizes the importance of health as part of its shareholder return system, enabling shareholders to experience the benefits of its technology firsthand [1] Group 2: Case Study - A 35-year-old shareholder participated in the annual shareholder reward activity and received a health screening, which led to the early detection of a tumor through a colonoscopy [1] - The shareholder had purchased BGI Genomics stock in July 2022 and underwent surgery in early July 2023, with a good recovery reported [1]

Core Insights - The article highlights a significant case where a shareholder of BGI Genomics, Mr. Han, credits the company's health screening service with saving his life by detecting early-stage cancer through a free genetic test [2][8]. Group 1: Company Initiatives - BGI Genomics launched the "2025 Annual Shareholder Return Activity," allowing long-term shareholders to receive free health screenings, which reflects the company's commitment to shareholder welfare and health [3][8]. - The company emphasizes its mission of "genetic technology benefiting humanity," aiming to improve public health and quality of life through the application of life sciences [9]. Group 2: Health Screening Impact - Mr. Han's experience illustrates the effectiveness of BGI's fecal DNA methylation testing, which can detect early signs of colorectal cancer, highlighting the importance of early screening in preventing severe health issues [10][12]. - The article notes that colorectal cancer is the second most common cancer in China, with a rising incidence among younger populations, underscoring the need for increased awareness and screening [10][12]. Group 3: Industry Context - The article discusses the challenges in colorectal cancer screening, including the low screening rates due to the invasive nature of traditional methods, and advocates for non-invasive tests like BGI's as a viable alternative [12]. - It emphasizes the importance of proactive health management, encouraging individuals to take charge of their health rather than waiting for symptoms to appear [12].

Group 1 - The core message highlights the successful early detection of colorectal cancer through the company's product, 华常康®, which saved a shareholder's life [2][3] - The company initiated a shareholder reward program in February 2023, providing health screening products to shareholders, which demonstrates its commitment to health and wellness [2][3] - Colorectal cancer is the second most common cancer in China, with a rising incidence among younger populations, emphasizing the need for early screening [2] Group 2 - The 华常康® product utilizes non-invasive fecal DNA methylation testing to assess cancer risk, addressing low screening rates due to the invasive nature of traditional methods [3] - The company has integrated health into its shareholder return system, allowing shareholders to experience the effectiveness and long-term value of its technology firsthand [3] - This initiative reflects the company's mission of using genetic technology to benefit humanity [3]

Group 1 - The core viewpoint of the news highlights the successful early detection of colorectal cancer through the non-invasive Hua Chang Kang testing product by BGI Genomics, demonstrating its significant value in early diagnosis [1] - A shareholder, Mr. Han, participated in the company's annual shareholder reward activity and received the Hua Chang Kang intestinal health testing product, which led to the early detection of his colorectal cancer [1] - The testing revealed three positive gene methylation results, prompting further examination that confirmed the presence of a tumor, which was successfully surgically removed [1] Group 2 - According to the National Cancer Center's 2024 data, colorectal cancer is the second most common cancer in China, with a rising incidence in urban areas and a concerning trend of younger patients [2] - The "Guidelines for Colorectal Cancer Screening and Early Diagnosis and Treatment (2020)" recommend early screening for high-risk groups, including those with a family history of colorectal cancer, previous polyps, or chronic intestinal diseases [2] - BGI Genomics' Hua Chang Kang product utilizes fecal DNA methylation testing to analyze specific gene changes, providing a sensitive and specific method for detecting precancerous lesions or early cancer signals [2]

Core Viewpoint - The medical device sector is experiencing a rise, with notable increases in stocks such as United Imaging Healthcare, New Industry, BGI Genomics, and Jiuan Medical, all rising over 3% [1] Group 1: Stock Performance - The ETF tracking the CSI All Share Medical Device Index has increased by approximately 3% [1] - Specific ETFs in the medical device sector have shown significant gains, with the Medical Device ETF Fund at 0.830, up 3.23%, and the Medical Device Index ETF at 0.588, up 3.16% [2] Group 2: Future Opportunities - Analysts indicate that increasing internationalization will provide more investment opportunities in the medical device sector, with several companies expected to see high growth in international business by 2025 [2] - The performance of Hong Kong's medical device stocks has been strong this year, which may positively influence the A-share market, suggesting that investment opportunities in both A-shares and Hong Kong's medical device sector will continue to emerge [2]

Core Viewpoint - As of August 5, 2025, BGI Genomics (300676) reported a closing price of 53.34 yuan, experiencing a decline of 0.78% with a turnover rate of 1.89% and a trading volume of 78,500 lots, amounting to 418 million yuan in transaction value [1] Financial Performance - For the first quarter of 2025, BGI Genomics reported total operating revenue of 672 million yuan, a year-on-year decrease of 18.18% - The net profit attributable to shareholders was 52.695 million yuan, a year-on-year decrease of 524.87% - The non-recurring net profit was 63.297 million yuan, a year-on-year decrease of 2,879.13% - The current ratio was 2.854, the quick ratio was 2.617, and the debt-to-asset ratio was 26.68% [1] Capital Flow - On the reporting day, the net outflow of main funds was 27.6854 million yuan, accounting for 6.63% of the transaction value - The net outflow of large orders was 21.3134 million yuan, accounting for 5.1% of the transaction value, while the net outflow of medium orders was 25.4012 million yuan, accounting for 6.08% - Small orders saw a net inflow of 2.2842 million yuan, accounting for 0.55% of the transaction value [1] Company Overview - BGI Genomics, established in 2010 and located in Shenzhen, primarily engages in professional technical services - The company has a registered capital of 4.15821575 billion yuan and a paid-in capital of 3.26119339 billion yuan - The legal representative of the company is Zhao Lijian [1][2] Investment and Intellectual Property - BGI Genomics has made investments in 71 companies and participated in 42 bidding projects - The company holds 665 trademark registrations and 374 patents, along with 13 administrative licenses [2]